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ABSTRACT 
Background: The American Cancer Society estimates that 72,570 people will be diagnosed 
with bladder cancer and 15,210 people will die from the disease in 2013. Radical cystectomy 
has been the standard treatment for decades, but the procedure is associated with significant 
morbidity and mortality. Currently, there are no preoperative tools which can help assess patient 
postoperative risk.  In this study, we address this need by creating a cystectomy risk calculator 
based on analysis of data from the American College of Surgeons’ National Surgical Quality 
Improvement Program (NSQIP).  
 
Methods: The NSQIP database was queried for cystectomy cases for bladder cancer between 
2005 and 2011. Fifty preoperative patient parameters and 74 postoperative outcomes were 
assessed, but only 32 independent preoperative variables had adequate sample size and were 
included in the stepwise logistic regression models for overall mortality and morbidity. 
Statistically significant variables were weighed and used to create a cystectomy risk calculator.   
 
Results:  From the NSQIP database, 1095 cystectomy cases were identified.  High 
preoperative BUN levels and previous PCI were predictive for increased postop morbidity risk. 
Previous cardiac surgery was associated with lower postop morbidity risk. Chemotherapy 
treatment within 30 days of surgery was associated with lower postop morbidity risk but 
increased postop mortality risk. Chronic steroid treatment and high preoperative WBC lab 
values were also associated with increased postop mortality risk.  
 
Conclusion: This study identifies significant predictive preoperative variables that inform 
postoperative complications following cystectomy.  The cystectomy risk calculator created gives 
physicians and patients a more precise estimation of individual risks of morbidity and mortality 
associated with the procedure. 
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 Introduction 
Based on 2005-2009 national data, the CDC ranks bladder cancer as having the 6th 
highest incidence rate among men and women combined.1 The burden of bladder cancer is 
large and rising, from stable rates of approximately 50,000 cases per year in the 1990s to over 
70,000 cases per year since 2010.1-3  The American Cancer Society estimates that 72,570 
people will be diagnosed with bladder cancer and 15,210 people will die from it in 2013.2 
Approximately 25% of incident cases are muscle-invasive (stage T2 or greater) at presentation, 
and a substantial plurality of patients presenting with high grade, non-muscle-invasive disease 
experience progression to muscle-invasive disease.4 The reference standard treatment for this 
potentially lethal phenotype is radical cystectomy, a complex extirpative and reconstructive 
procedure.   
Radical cystectomy has been the standard curative treatment for bladder cancer for 
decades, but patients undergoing radical cystectomy experience significant and highly variable 
risks of morbidity and mortality.5 Short-term morbidity such as postoperative ileus, infections, 
and cardiovascular complications affects anywhere from 34% up to 68% of patients reported in 
some studies,6,7 with 30-day mortality rates ranging from 1-4% in the whole population,7-9 and 
up to 21% in the elderly.9 In the last decade, robot-assisted radical cystectomies have been 
gaining ground, and while there have been some benefits associated with the reduction in 
operation time and length of stay, morbidity and mortality are still high, with morbidity ranging 
from 30-40% and 30-day mortality rates from 1-2%.10,11 The variability of risk for these 
undesired postoperative complications, and uncertainty about which variables are most strongly 
associated with increased risk, underscore the need for improved tools to support shared 
decision making. In addition, accurate risk stratification tools could help identify high-risk 
patients for novel intervention studies.  Previous attempts to understand the sources of risks of 
postoperative morbidity and mortality after cystectomy have largely been single-institution 
studies, with potentially limited generalizability.  In addition, data on risk factors have not been 
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collected using standardized prospective abstraction, limiting uniform ascertainment of 
potentially important outcomes. The relative dearth of high-quality data to inform risk 
stratification and counseling for patients facing the decision to undergo cystectomy creates a 
substantial opportunity for new urologic oncology research. 
To address this gap in the evidence, I use data from the American College of Surgeons’ 
National Surgical Quality Improvement Program (NSQIP) to examine factors associated with 
morbidity and mortality after cystectomy.  NSQIP was originally established by the Department 
of Veterans Affairs in 1994 to collect surgical data from all VA medical centers in the U.S. and 
create a unified database to monitor and evaluate the quality of surgical care. Over 110,000 
surgical cases with corresponding preoperative, intraoperative, and 30-day outcome variables 
were added to the NSQIP database annually. Based on the data, standardized protocols were 
created to improve surgical outcomes, with the observation of subsequent improvements in 
morbidity and mortality.12 In 2001, the American College of Surgeons expanded the NSQIP 
database to private hospitals, and in 2004, enrollment into NSQIP was opened to any hospital 
or health system that meets the participation requirements and agreements. Currently, 411 
hospitals across the U.S. are enrolled and reporting data, including UNC Hospitals.  These data 
have a number of exceptional strengths for the present study.  In contrast to prior studies in this 
context, the sample is nationally representative, and the data on risk factors, complications, and 
mortality are prospectively collected by trained chart abstractors.  In addition, the NSQIP data 
have been used to study other complex oncologic13,14 and non-oncologic15-18 indications to 
develop clinically applicable risk calculators addressing the outcomes of morbidity and mortality 
after surgery. 
The objective of this study is to develop a cystectomy risk calculator to predict 
postoperative morbidity and mortality based on preoperative clinical variables. The goal of the 
cystectomy risk calculator is to provide clinicians with a useful clinical tool that can estimate 
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post-operative morbidity and mortality risk. The tool will help physicians give patients a clearer 
understanding of their risks and alternate options and risk-stratify patients.  
 
Methods 
NSQIP Database 
The multicenter National Surgical Quality Improvement Program (NSQIP) database is 
compiled by surgical clinical reviewers who are trained by the American College of Surgeons 
specifically for NSQIP data collection. Data is collected prospectively and detailed information 
on inclusion and exclusion criteria, reviewer training, data abstraction and sampling are 
published and available.19-23 NSQIP monitors and evaluates for inter-rater reliability at random 
and monitors for internal hospital reliability. Data drawn from hospitals with discrepancies in 
their internal diagnostics will be audited to maintain a high level of internal validation.12 Between 
2005 and 2011, 1095 cystectomy cases were entered into the database using the International 
Classification of Diseases-9 (ICD-9) code category 188 which indicates primary malignant 
bladder cancer.  Data from these cases were used in this study to create a radical cystectomy 
risk calculator.  
Pre-operative variables 
We conducted a retrospective analysis of NSQIP data associated with cystectomy for 
bladder cancer using ICD-9-CM diagnosis codes (i.e. 188.0 (trigone), 188.1 (dome), 188.2 
(lateral wall), 188.3 (anterior wall), 188.4 (posterior wall), 188.5 (bladder neck), 188.6 (ureteric 
orifice), 188.7 (urachus), 188.8 (other specified sites) and 188.9 (part unspecified)).  One 
hundred and thirty five preoperative, perioperative and 30-day postoperative variables were 
assessed for this study. Each of the variables are defined and listed within the ACS-NSQIP data 
manual.23 
Fifty preoperative variables were evaluated for their capacity to predict a primary 
outcome of 30-day all-cause mortality and a secondary outcome of documented perioperative 
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and postoperative morbidity. Patient demographic variables that were used included age (<65, 
65-74, 75-84 and ≥85), sex, race, smoking status within one year and alcohol consumption 
(Table 1). Preoperative clinical factors included functional health status prior to current illness 
(independent, partially dependent, and null), functional health status prior to surgery 
(independent, partially dependent, totally dependent and unknown), dyspnea (at rest, with 
moderate exertion or none), BMI calculated based on height and weight (underweight <20, 
normal 20-24, overweight 25-29 and obese ≥30) and American Society of Anesthesiologists 
(ASA) classification (1=no systemic disease, 2=mild disease, 3=severe disease and 4=life 
threatening disease). Twelve preoperative blood lab values were also recorded including 
sodium, BUN, creatinine, total bilirubin, AST, alkaline phosphatase, WBC, hematocrit, platelet 
count, PTT, PT and INR. These values were left as numeric interval values.  
Comorbid conditions analyzed in the analysis included a history of severe COPD, 
ascites, hypertension requiring medication, congestive heart failure within 30 days prior to 
surgery, coronary heart disease (includes history of angina, history of myocardial infarction, 
previous percutaneous cardiac intervention or previous cardiac surgery), peripheral vascular 
disease (includes rest pain or history of peripheral vascular disease), neurological events 
(includes coma greater than 24 hours, history of TIA, CVA, CVA or stroke without neurologic 
symptoms, hemiplegia, quadriplegia, paraplegia), diabetes (grouped by insulin use, non-insulin 
use and no diabetes), dialysis use, steroid use for chronic condition, weight loss of >10% in the 
last 6 months, bleeding disorders, transfusions > 4 units of packed red blood cells within 72 
hours prior to surgery, chemotherapy or radiotherapy treatment conducted within 30 days of the 
surgery and presence of disseminated cancer. The frequencies and descriptions for these 
factors are listed in Table 2.  
Of the 50 preoperative variables evaluated, 18 were dropped due to small sample size 
(n<25 people) including functional health status prior to current illness, ventilator dependence, 
current pneumonia, ascites, CHF within 30 days of surgery, history of angina or MI, resting pain, 
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history of PVD, coma>24 hours, history of TIA or CVA, hemiplegia, quadriplegia, paraplegia, 
dialysis use, radiotherapy within 30 days, and tumor in the CNS. The remaining 32 preoperative 
variables were evaluated for predictive value for outcome of 30-day all-cause morbidity and 
mortality as reported until 2012.  
Postoperative Outcomes 
All postoperative outcome measurements documented in the ACS-NSQIP database 
were collected from a 30-day postoperative time frame regardless of continued hospitalization, 
discharge or re-hospitalization. The primary outcomes were postoperative overall morbidity and 
postoperative mortality.   
Postoperative diagnoses were based on ICD 9 coding. Morbidities include wound 
infectious (open, superficial surgical site infection, deep incision SSI, organ or space SSI and 
wound disruptions), pulmonary complications (includes pneumonia, pulmonary emboli and the 
need for >48 hours of ventilator use), renal complications (includes acute postop renal failure 
and progressive postop renal failures), urinary tract infections, neurologic and vascular 
complications (includes strokes, comas for >24 hours and peripheral nerve injuries), cardiac 
complications (includes myocardial infarctions and cardiac arrest requiring CPR), bleeding 
issues (includes deep vein thrombosis and thrombophlebitis) and systemic sepsis (includes 
sepsis and septic shock events). Reoperations were also documented and included as a 
postoperative morbidity event. The number of occurrences and days from operation until 
occurrences were recorded for each complication but only number of occurrences was used in 
the analysis.  
Postoperative mortality was measured by the number of postoperative deaths reported 
up until 2012. A total of in 74 postoperative variables were included in the outcome 
measurements and the combined morbidity as well as mortality dependent variables are listed 
in Table 3.  
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Statistical analysis 
All analysis was conducted using STATA 12 software. Descriptive and frequency 
analyses of all variables were conducted, and categorical variables were converted into numeric 
indicator variables as necessary. Stepwise multivariate logistic regressions were performed 
separately to assess for preoperative risk factors predictive of postoperative morbidity and 
mortality. The stepwise logistical regression was run in a forward-selection manner which 
allowed the STATA program to test and assess each preoperative variable and only add 
variables that improved the model’s predictive outcome. The STATA commands used to change 
the categorical variables to numeric are listed in Appendix 2. Missing data was dropped from 
the regression analysis. The two models were evaluated using Hosmer-Lemeshow goodness-
of-fit test to assess if the models were predictive of outcomes and the c-statistic test to measure 
how successful the models’ predictions are.  
Development of Risk Calculator 
 The risk calculator was created based on the equation for estimated cumulative 
probability for a multiple stepwise regression model which is as follows: 
Probability = 1/(1 + e
-(intercept + Coefficient1*X1 + Coefficient2*X2 +… + Coefficienti*Xi)
) 
Coefficients are derived from STATA stepwise logistic regression model, X represents each 
individual patient’s variable value and “i” represents the number of predictive variables that are 
included in the model. 
 
Results  
Patient characteristics 
From 2005 to 2011, the NSQIP database collected data on 1095 cystectomy cases. The 
average age of the study sample was 67 years old and 73.7% were male. The majority of the 
subjects reported that they had not smoked within one year of the procedure (75.4%) and did 
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not drink more than 2 drinks within 2 weeks of the procedure (96.3%). While this reported 
percentage of smokers is comparable to national rates in the U.S., the high association between 
smoking and bladder cancer does cast some doubt on how useful and accurate one-year 
abstinence from smoking is as a measurement for a study focused on bladder cancer.24 Over 
half of the patients in the study were classified as ASA class III (68.1%), with a quarter classified 
as ASA class II. Over 90% of the study population was Caucasian and roughly 5.5% were 
African American and 3% were Hispanic. Prior to the surgery, over 96% of the study population 
was classified as functionally independent and less than 1% was classified as totally dependent. 
In total, approximately 33% (n=358) of study participants experienced some postoperative 
morbidity and 3.47% (n=38) of the study participants died based on data collected up until 2012.  
Morbidity Model 
For postoperative morbidity, previous PCI procedures and high preoperative BUN labs 
were predictive of increased risk. A history of PCI procedures indicates that these patients suffer 
from underlying heart disease and may be at increased risk given their poorer cardiac baseline 
status. Furthermore PCIs are nonsurgical interventions that ameliorate symptomatic cardiac 
blockage as opposed to coronary artery bypass surgery or other invasive cardiac procedures 
that completely remove and replace blocked vessels. As such, PCIs are intermediate 
procedures that indicate a weakened cardiac system but do not actually correct the underlying 
cardiac condition nor test the patient’s ability to undergo and recover from an invasive surgical 
procedure which may explain its role as a positive predictor for post-cystectomy morbidity. 
Similarly, elevated BUN levels may also be an indicator of heart disease as it is often seen in 
patients suffering from heart failure. However, BUN is cleared from the body via urine, so 
patients with bladder cancer may have elevated BUN levels due to urinary obstruction or 
problems with urea removal. Given this study’s patient population, the implications of elevated 
BUN levels is unclear and may be multifactorial.  
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Previous cardiac surgery and chemotherapy treatment within 30 days of the surgery 
were also found to be predictive for postoperative morbidity, but they were found to be 
associated with decreased postoperative morbidity risk rather than increased. Though this may 
initially seem counter-intuitive, we believe that a history of cardiac surgery may be "protective" 
against post-cystectomy morbidity because these patients, in contrast to those with PCIs, have 
actually been “tested” and have successfully withstood and recovered from a seriously invasive 
surgical procedure.  These patients are also more likely to have gone through some form of 
post-surgery rehab and are more likely to have better and more consistent access to other 
forms of health care and thus, they may paradoxically be great candidates for later surgeries. 
Additionally, patients with a history of cardiac surgery may be considered "high risk" patients 
and undergo cystectomy surgeries at high-volume, high quality tertiary surgery centers which 
may also contribute to their decreased postoperative morbidity risk.  
Chemotherapy treatment within 30 days of surgery, however, was found to be predictive 
for decreased postoperative morbidity but also predictive for increased postoperative mortality. 
This dual effect suggests that patients who are receiving adjuvant chemotherapy treatment so 
close to the surgery may be likely to have a more aggressive or progressive form of bladder 
cancer and more likely to die rather than suffer multiple postoperative complications. However, 
this is not consistent with the current literature which reports significant data showing that 
perioperative adjuvant chemotherapy improves 5-year survival rates in both T0 stage bladder 
cancer as well as node positive patients.30 One explanation for the discrepancy may be the 30-
day timeframe specified in the NSQIP chemotherapy treatment variable which may be creating 
a select subgroup of patients as most patients receive perioperative adjuvant chemotherapy 
more than 30 days before their cystectomies. At this time, it is unclear how this specific time-
frame may be affecting the predictive postoperative outcomes for chemotherapy treatment or 
why these results are not consistent with the current literature on the benefits of perioperative 
adjuvant chemotherapy.  
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Mortality Model 
In addition to chemotherapy treatment, steroid treatment for chronic conditions and 
increased preoperative WBC labs were also predictive for increased postoperative mortality. 
Steroid treatment for chronic conditions was defined as oral steroid treatment that lasted longer 
than 10 consecutive days within 30 days of the procedure. Such treatment may be indicative of 
a weaker baseline health status and the treatment itself may also put these patients at 
increased risk of postoperative death as steroids can weaken immune defenses, increase 
patient susceptibility to postoperative infections and impede wound healing, all of which further 
elevate the risks associated with an invasive surgery such as radical cystectomies. Similarly, 
increased preoperative WBC labs may indicate that these patients are suffering from some 
underlying infectious or inflammatory response at baseline which puts them at higher risk for 
serious infectious complications leading to death postoperatively.  
Odds ratios for these variables are listed in Table 4. The Hosmer-Lemeshow goodness-
of-fit tests assessed that the models were predictive, and the c-statistics found that the morbidity 
model has a predictive value of 0.63 and the mortality model has a predictive value of 0.73.   
Risk Calculators 
The risk calculator for postoperative morbidity is as follows: 
Probability of Risk = 1/ (1 + e
-(-1.155 -0.945 (chemo) -0.929(pcs) + 0.028(bun) + 0.760(pci)
) 
The four preoperative values that are needed to calculate the cumulative postoperative 
morbidity risk for an individual patient are whether or not the patient has had chemotherapy 
treatment within 30 days of the procedure (chemo=1 if yes, chemo=0 if no), whether the patient 
has had previous cardiac surgery (pcs=1 if yes, pcs=0 if no), the preoperative lab BUN level 
entered as an integer (units of mg/dL) and if the patient has a history of PCI (pci=1 if yes, pci=0 
if no). 
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The equation for the risk calculator for the postoperative mortality model is as follows: 
Probability of Risk = 1/ (1 + e 
-(-4.293 + 0.101(wbc) + 1.445(chemo) + 2.693(steroid)
) 
To calculate postoperative morbidity risk, three preoperative values are needed. The 
preoperative white blood cell count, entered as an integer number, whether the patient has had 
chemotherapy treatment within 30 days of the procedure (chemo=1 if yes, chemo=0 if no), and 
whether the patient has had steroid use for a chronic condition within 30 days of the procedure 
which is defined as oral or parenteral steroid medications for longer than 10 days consecutively 
(steroid=1 if yes, steroid=0 if no).  
 
Discussion 
The National Surgical Quality Improvement Program is one of the strongest and most 
comprehensive surgical databases currently available in the U.S. The program draws from over 
400 different hospitals and health care systems and gathers data prospectively and 
systematically through a standardized sampling process that is subject to blinded review to 
assure high internal validity of reporting and data entry. Though there is some lack of variation 
for many of the 50 preoperative variables collected in relation to cystectomies, with some 
variable sets reporting less than 25 patients affected, the demographic distribution, complication 
and mortality rates recorded in the dataset are comparable to rates reported in the current 
literature, which suggests that this sample population is a fairly good representation of the 
national picture.  
Therefore the lack of variation is most likely due to one of two things: either we are not 
collecting information on the all of the pertinent variables or our current clinical practices are 
biased and preclude certain subpopulations from getting the procedure to begin with, thus 
leading to a select homogenous patient population. A review of the current literature, which 
overwhelmingly focuses the predictive value of three main preoperative variables—age, BMI 
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and comorbidity status—suggests that both factors are at play. The focus on these three 
variables is understandable as they are fairly easy to assess, especially when validated indices 
are used to measure comorbid status, and they intuitively seem like they should be predictive or 
associated with postoperative complications, especially given the invasive and serious nature of 
radical cystectomies. Yet, current studies have not found evidence that age or BMI are 
correlated with postoperative complications.25-27 Only moderate and severe comorbidity 
conditions were found to be predictive, but only as an aggregate preoperative status.28,29  
Our results are consistent with what has been reported in the literature. We also did not 
find age or BMI to be significant predictors for postoperative complications and mortality. We 
did, however, identify four specific preoperative factors that were predictive of postoperative 
morbidity and three specific factors that were predictive for postoperative mortality. The goal of 
our study was to build upon the current literature by identifying specific predictive values as 
opposed to relying on cumulative comorbidity status which can be misleading. We also set out 
to bridge the gap between statistical analysis and clinical practice by creating a risk calculator 
which physicians can use to assess patients’ post-cystectomy risks on an individual and 
specialized basis.  
This study has several limitations including selection bias and limited preoperative 
variables included in the analysis. The homogenous breakdown of race and preclinical variables 
in this dataset suggests that current clinical practice effectively limits the cystectomy procedure 
to patients who are, for the most part, healthy and without significant comorbid or preoperative 
conditions on a national level. Examination of elevated BMI and advanced age as predictors of 
postoperative complications is obscured by pervasive selection bias for the healthiest elderly or 
overweight/obese patients since these two clinical variables are considered independent risk 
factors in general. This is particularly problematic in this study, given the natural 
pathophysiology of bladder cancer, which appears later in life and is associated with smoking, 
which is independently associated with many comorbid conditions. However, this selection bias 
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has a diluting effect on our results, meaning that we are more likely to be underestimating 
significant associations rather than overestimating them. Furthermore, the selection bias against 
operating on unhealthy and elderly patients is limited by real-world expectations and practices 
and cannot be fully controlled for. Another limitation of this study is the use of a pre-established 
database that is not specific or tailored to bladder cancer. We are limited to the variables that 
have been chosen by the ACS and may be missing out on variables that are uniquely pertinent 
to bladder cancer risk estimation including gastrointestinal complications such as postoperative 
ileus which is one of the leading complications associated with cystectomies.  
As mentioned above, the ACS-NSQIP database has been used to create similar risk 
calculators for respiratory failure, 17 bariatric surgery,16 and hepato-pancreato-biliary surgery14 
among others. Though the clinical success of these calculators are yet to be determined, the 
historical success of similar tools such as the Framingham heart calculator, Cleveland Clinic 
stroke calculator and the World Health Organization fracture risk assessment tool are promising 
examples of what evidence-based data analysis can yield. Though this study draws from one of 
the largest national surgical databases currently in existence in the U.S., there is a notable lack 
of variance among the patients studied. The homogenous nature of the data suggests that 
clinical and research policy efforts may be needed to help change current biases in surgical 
decision-making in order to expand the patient population and to help create stronger evidence-
based tools for patients and physicians.  
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Table 1: NSQIP Patient Demographics and Preoperative Variables  
Variables Frequency/N 
Total Cases 1095 
Age (yrs), mean ± SD 67.5 ± 11.4 
Sex, % Male 73.65% (n=805) 
Smoker, % (smoked within 1 yr of surgery) 24.57% (n=269) 
Drinker, % (2 drinks/day in 2 wks of surgery) 3.74% (n=41) 
Race   
   White 90.43% (n=860) 
   Unknown 13.15% (n=144) 
   African American 5.47% (n=52) 
  Hispanic 3.15% (n=30) 
  Other 0.95% (n=9) 
BMI    
   Underweight 3.65% (n=40) 
   Normal 28.58% (n=313) 
   Overweight 34.98% (n=383) 
   Obese 32.79% (n=359) 
Diabetes, %   
     None 80.27% (n=879) 
     Non-insulin treatment 13.88% (n=152) 
     Insulin treatment 5.84% (n=64) 
ASA classification    
   1-No Disturbance 1.0% (n=11) 
   2-Mild Disturbance 25.39% (n=278) 
   3-Severe Disturbance 68.13% (n=746) 
   4-Life Threatening Disturbance 5.48% (n=60) 
Functional Health Status Prior to Surgery   
     Independent 95.98% (n=1051) 
     Dependent  3.93% (n=43) 
Dyspnea  
     None 89.13% (n=976) 
     Yes 10.87% (n=119) 
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Table 2: NSQIP Collapsed and Numeric Indicator Variables Left in the Analysis 
H/o COPD 0 (No): 1005=91.78% 
1 (Yes): 90= 8.22% 
Hypermed Indicator Var 0 (No): 470= 42.92% 
1 (Yes): 625= 57.08% 
Diabetes Indicator Variable 0 (None): 879=80.27% 
1 (Yes): 216= 19.73% 
Previous PCI 0 (No): 1001 = 91.42% 
1 (Ye)s: 94=8.58% 
Previous cardiac surgery 0 (No): 1007: 91.96% 
1 (Yes): 88=8.04% 
Steroid Indicator Var 0 (No):1065 =97.26 % 
1 (Yes): 30= 2.74% 
Wt loss Indicator Var 0 (None): 1054= 96.26% 
1 (Yes): 41= % 
Bleed disease Indicator Var 0 (No): 1062= 96.99% 
1 (Yes): 33= 3.01% 
Transfusions Indicator Var 0 (No): 1060= 96.80% 
1 (Yes): 35= 3.20% 
Chemotx Indicator Var 0 (No): 1006= 91.87% 
1 (Yes): 89= 8.13% 
Disseminated cancer 0 (No): 1018= 92.97% 
1 (Yes): 77=7.03% 
 
 
 
  
Condition Frequency/Descriptive 
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Table 3: NSQIP Postoperative Conditions 
*Note: for the complications, “occurrences” are categorical data and “numbers” is the numeric 
form of the same data. 0=No incidence 1=Incidence 
 
Condition Designation Frequency/Descriptive 
Number of open wound/wound 
infection 
Wndinf 0: 1072=97.90% 
1: 23=2.10% 
Number of Superficial wound 
occurrences 
Nsupinfec 0: 1016 =92.79% 
1: 79=7.21% 
Number of deep incisional SSI 
occurrences 
Nwndinfd 0:1078=98.45% 
1: 17=1.55% 
Number of Organ/Space SSI 
occurrences 
Norgspcssi 0: 1044=95.34 
1: 51=4.66% 
Number of wound disruption 
occurrences 
Ndehis 0 : 1,064 = 97.17% 
1 : 31 = 2.83% 
Number of pneumonia occurrences Noupneumo 0: 1,055 = 96.35% 
1:  40 = 3.65% 
Number of unplanned intubation 
occurrences 
Nreintub 0: 1,062  = 96.99 % 
1: 32 = 2.92% 
2: 1 = 0.09% 
Number of PE occurrences Pulembol 0: 1,063  = 97.08% 
1 : 32 = 2.92 % 
Number of on ventilator>48 hours 
occurrences 
Nfailwean  0: 1,066 = 97.35% 
1: 28 = 2.56% 
2: 1 = 0.09% 
Number of progressive renal 
insufficiency occurrences 
Nrenainsf 0: 1,067 = 97.44% 
1: 27 = 2.47% 
2: 1 = 0.09% 
Number of acute renal failure 
occurrences 
Noprenafl 0:1076 = 98.26% 
1: 19= 1.74% 
Number of urinary tract infection 
occurrences 
nurninfec 0: 991=90.50 
1: 104=9.50% 
Number of stroke/CVA occurrences Ncnscva 0: 1090=99.54% 
1: 5=0.46% 
Number of coma>24 hours 
occurrences 
Ncnscoma 0: 1095=100%  
Number of peripheral nerve injury 
occurrences 
Nneurodef 0: 1092 = 99.73% 
1: 3=0.27% 
Number of cardiac arrest requiring 
CPR occurrences 
Ncdarrest 0: 1085=99.09% 
1: 10 = 0.91% 
Number of myocardial infarction 
occurrences 
Ncdmi 0: 1082 = 98.81% 
1: 13 = 1.19% 
Number of bleeding transfusions 
occurrences 
Nothbleed 0: 779=71.14% 
1: 314 = 28.68% 
2: 2 = 0.18% 
Number of DVT/Thrombophlebitis 
occurrences 
Nothdvt 0: 1049 = 95.80% 
1: 46 = 4.20% 
Systemic sepsis Prsepis Null: 15=1.37% 
None: 1061=96.89% 
SIRS: 13=1.19% 
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Sepsis: 6=0.55% 
Number of sepsis occurrences Nothsysep  0: 982 = 89.68% 
1: 113= 10.32% 
Number of septic shock occurrences Nothseshock 0: 1057 = 96.53% 
1: 38 = 3.47% 
Reoperation Reoperation Null: 21=4.48% 
No: 426=90.83% 
Yes: 22=4.69% 
Year of death 
- Missing data: 1,057=  96.53% 
 
Yrdeath 2008 |     4 = 0.37% 
2009 |     6 = 0.55% 
2010 |     14 = 1.28% 
2011 |     13 = 1.19% 
2012 |     1 = 0.09% 
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Table 4: Morbidity and Mortality OR and 95% CI 
ACS NSQIP Variables Freq./ Mean ± SD Overall Morbidity  
OR (95% CI) 
Overall Mortality  
OR (95% CI) 
Preoperative BUN 18.88 ± 8.94 1.03 (1.002-1.056)   
Previous Cardiac Surgery 8.04% (n=88) 0.40 (0.159-0.983)   
Previous PCI 8.58% (n=94) 2.14 (1.007-4.540)   
Chemotherapy treatment (<30 d) 8.13% (n=89) 0.39 (0.153-0.989) 4.24 (1.035-17.381 
Steroid treatment 2.74% (n=30)   14.78 (2.115-103.288)* 
Preoperative WBC 7.79 ±3.14   1.11 (1.010-1.212) 
        
Hosmer-Lemeshow p   6.27 (p=0.6172) 7.24 (p=0.5110) 
C Statistic   0.6299 0.7251 
*p<0.01 
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Figure 1: LROC for Morbidity Model  
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Figure 2: LROC for Mortality Model 
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Appendix 1: Preoperative Predictors of Postoperative Radical Cystectomy 
Complications: A Systematic Review 
 
Patients with bladder cancer are diagnosed, on average, at the age of 73 based on 2006 
to 2010 SEER data.3 The advanced age of bladder cancer patients is associated with increased 
comorbidity which adds to the already high level of risks associated with cystectomies. Smoking 
exposure, either firsthand or secondhand, is also significantly associated with the development 
of bladder cancer, with recent studies reported that smoking is associated with up to 50% of all 
diagnosed bladder cancer cases.31 Smoking has also been shown to contribute to coronary 
heart disease, lung disease and several other health conditions.32 Given the multitude of 
comorbid and confounding factors associated with bladder cancer, it is clinically important to 
identify the preoperative factors that are significantly predictive or associated with postoperative 
complications and those that are not. Correct identification would allow physicians and patients 
to better understand and estimate individual risks associated with radical cystectomies. This is 
especially important in the bladder cancer demographic because it may correct certain biases 
associated with the elderly population undergoing invasive surgical procedures and increase the 
effectiveness of care.  
Methods 
I conducted a systematic review of the literature to examine which pre-operative 
variables best predict post-operative (hereafter “pre-op” and “post-op”) radical cystectomy 
complications, as reported in the literature. My review is restricted to literature on human 
patients who underwent radical cystectomy, with no preference for robotic or open surgery. I 
searched for outcomes of any post-op complications including mortality, morbidity, re-operation 
and re-hospitalization.  
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I included all published study types except for single case studies. For inclusion, study 
populations had to be bladder cancer patients who had undergone radical cystectomy and 
studies had to include pre-op measures of variables and comorbid statistics as well as post-op 
complications of the surgery. I excluded studies that focused on pre-op cancer or genomic 
predictors and markers or looked at post-op outcomes related to chemotherapy and specific 
cancer genomics rather than surgery.   
The sentinel study that best exemplifies the review question is “Associations between 
comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: 
results from the Alberta Urology Institute Radical Cystectomy database” published in 2009 by 
Fairey et al. I used the Medline search terms tagged to the article in PubMed to come up with 
the following key search terms for this systematic review:  comorbidity, treatment outcome, risk 
assessment, cystectomy/methods. I used these search terms in three different combinations of 
phrases in PubMed.  
  I used the following search terms: “cystectomy AND comorbidity AND treatment 
outcome” yielded 33 results including the Fairey sentinel study as well an older Fairey study that 
is also based on the same Alberta Urology Institute database.  I used the following limitations for 
all searches:  English language, with abstracts, and human. I conducted this final search on 
January 15, 2013. The 33 studies generated by PubMed are listed in List 1. I assessed titles 
and abstracts of all 34 studies and removed 23 articles at this stage based on inclusion and 
exclusive criteria. The reasons for exclusion of each of the 23 articles are listed in List 2. I then 
assessed the remaining 11 articles in full (Table 1) for inclusion in the review. I excluded article 
number 34 because the full article was not available. The final 10 articles were each assessed 
for methodological quality as outlined in Table 2. A graphic depicting the flow of study inclusion 
in this review is included in Figure 1.  
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Discussion 
 The 10 articles included for analysis examined the predictive relationship between 
preoperative factors, such as age, comorbidity status and BMI, and postoperative outcomes in 
patients who received a radical cystectomy as treatment for bladder cancer. Of the 10 articles, 
nine were retrospective cohort analyses and one was a cohort study that spanned 7 years. 
Three studies focused on the combined predictive power of age and comorbidity status on 
postoperative complications and mortality rates. Two studies focused only on advanced age, 
two focused only on comorbidity status and two studies focused on BMI and obesity as 
predictive factors of postoperative complications. The final study included in the analysis 
examined gender differences on perioperative blood utilization and post-op length of stay. 
Though postop medical and surgical complications were included as secondary outcomes, 
gender was used as the main independent variable in these analyses as well despite the study 
population comprising of only 24% female participants. Given this limitation in the study’s power 
and the fact that postoperative complications, the main focus of my question, were treated as 
secondary outcomes, this study was not included in further analysis.  
Age and Comorbidity 
 The three studies that examined the relationship between age and comorbidity and 
postsurgical outcomes provided the most comprehensive answer to my question. The results of 
the studies indicated that advanced age was not a significant independent prognostic factor for 
postop complications or 90-day mortality, but did find that moderate and severe comorbidity 
status when adjusted for age was predictive of both. Though all three are retrospective cohort 
studies with similar results, the studies differed in strength of design and analysis and all have 
important limitations.  
The 2008 retrospective cohort study conducted by Fairey et al. had the strongest study 
design and was conducted by the same group as the sentinel article used for this literature 
review.25 For both studies, Fairey et al. used the Albert Urology Institute Radical Cystectomy 
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database which is a multi-institutional computerized database that collects patient demographic 
data (sex, age, weight, height and smoking history) as well as operative information including 
perioperative therapy, type of surgery, extent of lymphadenopathy dissection and type of urinary 
division constructed. The database also collects pathology information including staging, grade, 
surgical margins, histological type and number of lymph nodes removed. All patient data 
collected between 2000 and 2006 were gathered retrospectively but beginning in 2007, data 
has been collected prospectively. For this study, Fairey et al. used data from 314 consecutive 
patients who had undergone radical cystectomy and were enrolled into the database between 
2000 and 2006. The primary outcome for the study was 90 day mortality and early post-
operative complications. Comorbidity status was measured by adult comorbidity evaluation 27 
(ACE 27) scores which are divided into mild, moderate and severe categories. Cox proportional 
hazards regression analysis was used to assess predictive value when adjusted for age, sex, 
surgeon volume, type of urinary tract reconstruction and staging of the original cancer. Results 
showed that moderate comorbidity was associated with minor (OR 2.1) and major (OR 11.4) 
early postop complications with an overall predictive value of OR 5.2 for all early postop 
complications. Severe comorbidity showed an even stronger association with all three outcome 
measures (OR 2.2, OR 15.2 and OR 7), but age was not found to be a significant independent 
predictor. The results, however, are limited by certain under-represented demographics in the 
study population. Only 18% of 314 patients were categorized as having severe comorbidity, The 
small number of octogenarian study participants may have diluted the predictive value of age 
and pushed the findings towards the null.  Additionally, the age of the study population, with a 
mean of 66 years old and standard deviation of 10 years, limits the external generalizability 
given that the average age of patients diagnosed with bladder cancer is 73 years old.3  
Koppie et al.’s 2008 study, however, has even more limitations in its study design and 
results. Though they had the largest sample size of all 10 articles included in the review, with a 
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total of 1121 patients, all of the patients came from a single center which significantly limits the 
external validity of the study.29 Moreover, Koppie and colleagues were unable to acquire 
pathology and histology data-points for the subjects, which precluded their ability to adjust for 
differing disease burden. So it is unclear whether patients with higher comorbidity scores, 
measured by age-adjusted Charlson comorbidity scores (ACCI) in this study, also had higher 
disease burden or more progressive disease genotypes to start with, which would confound 
their finding that higher ACCI scores were associated with lower overall survival. This 
unaccounted confounder significantly limits the power and validity of the study results. Koppie 
and colleagues also did not do a good job of measuring postoperative complications. Aside from 
overall survival, the primary outcome measures were number of lymph-node dissections, 
number of lymph node evaluations and postop chemotherapy treatments, none of which 
measures complication or morbidity resulting directly from the surgical procedure. Additionally, 
this study used ACCI scores as measured of comorbidity instead of ACE 27 scores. Though 
both indices have been validated, ACCI scores have been shown to be a less powerful predictor 
of 90-day perioperative mortality than the ACE-27 index which Fairey et al used (OR 1.72 vs. 
OR 1.31).33  
The last study in this group, Liguori et al.’s 2006 retrospective analysis, has the weakest 
design and execution. Though the study lists a sample size of 55 patients, only 20 patients had 
undergone a radical cystectomy, while the other 35 were treated with radical nephrectomies or 
nephreoureterectomies.34 Since the study question is focused on the complications and 
mortality associated with radical cystectomies, only the 20 patients who underwent radical 
cystectomies are relevant to this review. This limited number not only decreases the study’s 
power, but also makes it difficult to identify the relevant results since the researchers did not 
conduct a stratified analysis based on the surgical procedure that was performed. Another 
problem is how the study measured patient comorbidity. Instead of using CCI, ACE 27 or 
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another validated comorbidity index, the researchers used the number of specific comorbid 
conditions that each patient had as the comorbidity input measure. Though each patient was 
graded according to the ASA classification system, ASA scores were not reported in the results. 
The results of the student t and chi-square analysis showed that chronic obstructive lung 
disease was independently associated with postoperative morbidity (p<0.017). The presence of 
two or more comorbid conditions was also reported as predictive for morbidity (p< 0.05). 
However, given the small sample size, a p<0.05 is not very significant. This study also reported 
that age was not found to be an independent prognostic factor. Although these results are 
largely in line with those reported in the other two studies, this study is very limited and weak.  
 The other studies included in the analysis are less comprehensive and focus on the 
predictive value of a single preclinical factor, but the results are largely cohesive and supportive 
of the results reported in the first three studies.  
 
Age  
Horovitz et al. and Lau et al. examined the predictive value of advanced age for 
postoperative survival and did not find any evidence suggesting that age was associated with 
different postoperative mortality rates. Though postoperative survival is relevant to my question, 
neither study included any measures of postoperative complications, which are more common 
and directly related to the surgical procedure itself. Postoperative mortality, though important, is 
a complex outcome measurement that is affected by many cofounders which were not 
controlled for in either study. 
Horovitz and colleagues conducted a retrospective analysis of 605 patients who 
underwent radical cystectomy.26 The patients were drawn from two databases, one in Canada 
and the other in Finland. Patient were divided into four different age groups (≤59, 60-69, 70-79 
and ≥80) and multivariate logistical regression analysis was conducted to evaluate for 
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differences in recurrence-free survival, disease-free survival and overall survival as the primary 
outcomes. The retrospective study design presents several problems for the study’s strength. 
The patients who underwent radical cystectomy, especially those with advanced age, were 
specifically chosen and likely to have been more rigorously vetted to undergo such an invasive 
procedure. This would result in a selection bias that would push the results towards the null. For 
example, the older patients who are chosen may have less aggressive or lower burden of 
disease as compared to younger patients. The surgeons may also approach the elderly patients 
with a more aggressive surgical approach such as cutting wider surgical margins or dissecting 
more lymph node as compared to younger patients. In the Horovitz study, there was no 
difference in the postoperative survival rates for the different age groups.26 The researchers 
were able to collect clinical, pathological and treatment data retrospectively for the patients and 
adjust for age-related differences with multivariate logistical regression. Though this may help 
control for baseline age-related differences in disease pathology and staging, the results 
showed that the octogenarian patients had a statistically greater number of lymph nodes 
removed (p≤0.001) and less postoperative adjuvant treatment (p≤0.001) when compared to the 
other age groups. This difference may reflect a more aggressive surgical approach with less 
need for adjuvant treatment. Such differences in the treatment approaches between the age 
groups would be a major confounder that would push the results towards the null. In a 
retrospective analysis, this confounder would be hard to identify, measure and control for which 
weakens the power of the study’s results.   
The second study that focused on advanced age actually did not address my research 
question. Lau et al.’s cohort study did not analyze the predictive value of age on outcomes; 
instead, they gathered morbidity and mortality data on 23 octogenarian patients who received 
robotic radical cystectomies from one institution and compared it to outcome data for 
octogenarians who had undergone open radical cystectomies in other studies.35 They did not 
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find any significant difference in morbidity and mortality rates between the two types of radical 
cystectomy procedures conducted among octogenarian patients. They also did not conduct any 
analysis using advanced age as a predictive preoperative factor.  
 
Comorbidity 
In addition to age, comorbidity was also studied as a possible independent predictive factor for 
postoperative survival and complications. One of the two studies that focused on this question 
was the 2009 article written by Fairey et al. which was used as the sentinel article for this 
systematic review search. The Fairey et al. 2009 study and the Zhu et al. 2012 study are both 
retrospective cohort analyses that used the ACE 27 index as an indicator of comorbid status. 
Both studies found that moderate and severe comorbidity were associated with increased 
overall postoperative mortality rates as well as cancer-specific mortality rates. These findings 
agree with the results reported in the first three studies which examined the combined predictive 
value of age and comorbidity status on postoperative outcomes.  Though the results from the 
Fairey and Zhu studies support each other, the study populations, calculated hazard ratios and 
the limitations lend different power to the studies’ results.  
The 2009 Fairey et al. study, similar to the 2008 retrospective cohort study that looked at 
comorbidity and age together as predictive factors for postop complications, used the Albert 
Urology Institute Radical Cystectomy database. As mentioned above, the database is a multi-
center database that collects demographic, clinical and pathological data for hundreds of 
patients who have had a radical cystectomy. In this study, 468 patients were divided into three 
categories based on the severity of their comorbidity status as measured by the ACE 27 index.28 
One hundred and sixty patients were assigned to the no or mild comorbidity category, 225 to the 
moderate category and 83 to the severe category. The disproportionately small number of 
patients placed in the severe category (18% of the sample population) introduces selection bias 
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that may dilute any existing association and push the results towards the null. This may explain 
why the calculated hazard ratios for the strength of association between comorbidity and overall 
postoperative mortality rates in the Fairey study (moderate comorbidity HR 1.59, severe 
comorbidity HR 1.83) are smaller than the hazard ratios calculated in the Zhu et al. study 
(moderate comorbidity HR 2.217, severe comorbidity HR 10.431).  
However, the results reported in the Zhu et al. study must be read with caution. The 
study looked exclusively at the Chinese population, and the study population was drawn from 
one hospital center in China which limits the external generalizability of the study results.36 
Internal validity is also a concern because clinical and surgical treatment for bladder cancer 
differs in China as compared to developed countries, in part because of differences in medical 
regulation and standardization.37 Such differences in treatment decisions, surgical approach and 
surgical experience could be a confounding factor that may contribute to the higher calculated 
hazard ratios for moderate and severe comorbidity status and overall postoperative survival. 
Another possible contributing factor is the small study sample size. Though Zhu et al. initially 
enrolled 305 patients, 59 patients were excluded due to incomplete clinical or pathological data, 
adjuvant chemotherapy or radiotherapy treatment or a histological diagnosis other than 
transitional cell carcinoma. Of the 246 patients ultimately enrolled in the study, 151 patients died 
during the follow-up period which equated to a loss of approximately 61% of the study 
population. This is a significantly higher mortality rate than those reported in other radical 
cystectomy studies, which suggests that there may be other factors contributing to 
postoperative complications and mortality besides the surgical procedure itself. Again, some of 
these factors may be specific to the practice of medicine, treatment options, surgical experience 
or differences in health care access and literacy seen in China as compared to the U.S., none of 
which was adjusted or accounted for in the study. Moreover, smoking, which is directly related 
to increased risk for bladder cancer and many comorbid conditions, is more prevalent among 
36 
 
the Chinese population as compared to the U.S. population,38 and smoking status as a 
confounder was not controlled for in the Zhu et al. study in any way which further weakens the 
study’s results.  
 
BMI 
The independent predictive value of body-mass index on postoperative outcomes was 
also studied. The effect of obesity, often measured by BMI, on perioperative and postoperative 
complications is unclear. Some studies have shown weak and moderate correlations between 
higher BMIs and increased perioperative and postoperative risks for thoracic, orthopedic, 
transplant, reconstructive and many other types of surgeries,39, 40, 41, 42 and other studies have 
not found any correlation, including studies specific to other urologic surgeries including robotic-
assisted laparoscopic prostectomies.43, 44 Two studies examining the impact of high BMI on 
outcomes following radical cystectomies were included in this review. Neither study found a 
significant association between BMI and postoperative complications; however, postoperative 
complications were secondary outcomes in both studies. The two studies primarily focused on 
examining BMI-related differences in cost, blood loss and mean operative time as primary 
outcome measurements.  
Bagrodia et al.’s 2008 retrospective analysis focused primarily on BMI-related 
differences in hospital costs. Demographic, clinical, treatment and pathology data was collected 
from 99 patients who had undergone radical cystectomies at one institution between 2004 and 
2007.45 The patients were stratified into three categories based on BMI (normal <25 (n=27), 
overweight 25-30 (n=38) and obese ≥30 (n=34)), and the study used the ACE 27 index and 
ECOG scores to evaluate comorbidity status. The hospital involved in the study is a tertiary 
surgical center that has more experience treating obese patients than many other surgical 
centers in the country, which limits the external generalizability of the study’s findings. Analysis 
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also showed that patients in the obese strata had the lowest median age and the lowest 
average ECOG scores out of the three BMI groups, which suggest that the obese patients 
selected for surgery were healthier than the other two groups. This selection bias is 
unaccounted for, and when combined with the small sample size, can significantly push the 
results towards null and dilutes any correlation between BMI and postsurgical complications that 
may exist.  
The second study, conducted by Butt et al, also did not report any significant association 
between BMI and postoperative complication rates. Though Butt et al.’s 2008 study is also a 
retrospective analysis, the researchers used data gathered from standardized medical record 
forms which prospectively collected data on 49 consecutive patients who underwent radical 
cystectomies between 2005 and 2007.27 The standardized prospective collection of data 
increases internal validity and strengthens the analysis and results. Nonetheless, Butt and 
colleagues faced similar limitations in external generalizability and sample size.  Butt and 
colleagues had an even smaller sample size of 49 patients who were stratified based on BMI 
(BMI<25 (n=14), BMI 25-29 (n=18), BMI ≥30 (n=17)), and the patients were also drawn from a 
single center. The primary research outcomes, which focused on differences in mean operative 
time, blood loss, time to urinary diversion, surgical margins and time for lymph node dissection, 
also did not directly apply to my study question.  
 
Conclusion 
Despite the high morbidity and mortality associated with radical cystectomy, a review of 
the literature for preoperative predictors of postoperative outcomes of the surgical procedure 
yielded limited information. After multiple PubMed searches, nine studies evaluating 
preoperative predictors not associated with cancer genetics or adjuvant therapy treatments 
were identified. Three preoperative predictors—advanced age, comorbidity status and obesity 
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as measured by BMI—were examined either independently or in combination among the nine 
studies. Three studies examined the combined effect of age and comorbidity status, two 
examined age alone, two examined comorbidity alone and two examined the predictive value of 
BMI. Age and BMI were not found to have any significant correlation or predictive value for 
postoperative mortality or postoperative complications. Only moderate and severe comorbidity 
status was found to be predictive of increased postoperative complications and increased 
postoperative mortality rates.  
Though none of the nine articles included in the review reported findings that 
contradicted each other, the studies all had relatively small sample sizes and limited external 
validity. All but one of the studies was a retrospective analysis, which is one of the weakest 
study designs and involves a high level of recording and reporting bias. Retrospective studies 
are also vulnerable to significant selection bias, which was particularly problematic in the studies 
that focused on the predictive value of age and BMI. Since patients with advanced age and 
elevated BMI’s are often considered to be at higher risk for surgical complications in general, it 
is likely that the elderly and obese patients who underwent radical cystectomies in the 
retrospective studies were a healthier subset that were differentially selected by surgeons and 
providers. This selection bias would push the results towards the null, which is consistent with 
what was reported. Additionally, some of the studies, such as Horowitz et al., Koppie et al. and 
Zhu et al.’s studies, did not account for or control for confounding factors such as differences in 
surgical approach and differential smoking rates among the study groups. Moreover, among the 
five studies that examined the predictive value of comorbidity, various measures including the 
ACE 27 index, ASA, Charlson, age-adjusted Charlson and ECOG score were used to quantify 
comorbidity. Though all five indices are validated comorbidity measurements and shown to be 
good predictors of cancer-independent mortality for radical cystectomy, these indices have not 
been shown to be good predictors of postoperative complications which are more common than 
postoperative mortality associated with radical cystectomy.33,46  
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In general, the data uncovered by this literature review are weak, unspecific and drawn 
from a limited study population. Five of the nine studies used data from a single center, and the 
other four recruited small numbers of study patients from two medical centers. The majority of 
the studies used data gathered from tertiary and high-volume medical centers which also limits 
the external generalizability of the findings. Furthermore, the only positive predictive 
preoperative factor, moderate to severe comorbidity, was not uniformly measured and was 
reported to have differing degrees of predictive value. One of the biggest limits to the strength of 
the results is the retrospective approach to data analysis. Only one of the eight retrospective 
analyses used a standardized form to prospectively collect patient data, and the form was not 
specific to demographic, clinical or pathological conditions that are particularly relevant bladder 
cancer. This literature review does not sufficiently answer the question of what preoperative 
factors are predictive of post-radical cystectomy complications, and it is clear that more 
standardized, multi-center, large powered studies are needed in order to better estimate and 
calculate such risks for patients with bladder cancer.   
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chemo/rad
iotx, 16 for 
incomplet
e 
clin/path, 
30 not  
transitiona
age, 
gender, 
delayed 
time of 
radical 
cystectomy, 
urinary 
diversion 
type, pelvic 
lymphadene
ctomy 
status, TNM 
1. Overall 
survival 
shown by 
Kaplan-Meier 
log-rank for 
overall 
survival.                         
2. Cox 
proportional 
hazards 
regression 
for risk 
Multivariate 
decreased survival 
was associated with:           
1) Age: ≥70 HR 
2.217                            
2) Comorbidity: HR 
2.217 for moderate, 
HR 10.431 for sev 
ere                  3) 
Delayed time: ≥12 
weeks HR 1.681                              
4 ) >T3: HR 5.408                                        
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diversion.             l cell ca.     
215 
male/31 
female 
stage, and 
pathological 
grade, ACE 
27 index 
factors.  5) Lymphadenectomy 
inc survival: 0.623                                                                    
 
Univariate but not 
Multi analysis 
showed that:                            
6) Urinary diversion 
type were not 
significantly different           
7) >G2 staging not 
sig 
 
1922024
4 
Bagrodia A, 
Grover S, 
Srivastava 
A, Gupta A, 
Bolenz C, 
Sagalowsky 
AI, Lotan Y. 
Impact of body 
mass index on 
clinical and 
cost outcomes 
after 
radical cystect
omy. 
2008 Retrospectiv
e analysis 
Patients all 
from one 
hospital, 
surgeries 
done 
between 
2004-2007. 
Patients 
were 
stratified by 
BMI: 
normal <25 
(27%), 
overweight 
25-30 
(38%) and 
obese 
>=30 
(24%).   
n=99 age, sex, 
BMI, 
comorbiditie
s via ASA 
score, 
ECOG 
score, 
neoadjuvant 
chemothera
py. 
Pthology: 
tumor size, 
multiple?, 
stage, final 
pathology, 
node 
positivity. 
Clinical: 
LOS, 
transfusion, 
diversion 
type, 
complication
s.  
1. Cost 
2. 
Complication 
Mainly looked at 
differences in cost.  
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1876504
5 
Butt ZM, 
Perlmutter 
AE, 
Piacente 
PM, Wilding 
G, Tan W, 
Kim HL, 
Mohler JL, 
Guru KA. 
Impact of body 
mass index on 
robot-assisted 
radical cystect
omy. 
2008 Retrospectiv
e analysis 
BMI<25 
(n=14), 
BMI 25-29 
(n=18), 
BMI >=30 
(n=17).  
n=51 
consecutiv
e patients 
2005-
2007. But 
final 
involved 
count = 49 
Age, sex, 
BMI, ASA 
scores, 
pathological 
state 
mean 
operative 
time overall, 
mean 
operative 
time for LND, 
mean blood 
loss, time to 
create a 
urinary 
diversion, 
surgical 
margins, 
postop 
complication
s 
Used p values:  
1) Outcome 
measures mostly 
trended upward with 
BMI, but were not 
significantly 
associated. 2) No 
significant difference 
in blood loss among 
the three groups. 3) 
No difference in 
primary tumor stage, 
but overweight cohort 
were more likely to 
have positive surgical 
margins (p=0.050.  
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Figure 1 
 
 
 
 
  
 
Potentially relevant 
publications identified using 
search terms:  “cystectomy 
AND comorbidity AND 
treatment outcome” in PubMed 
on 1/15/2013. (n= 34)  
Papers retrieved for evaluation 
of the full article. (n=11)   
Papers excluded on 
basis of title and abstract 
(generally due to focus 
on cancer markers, or 
comparison to alternative 
treatments). (n=23) 
Paper excluded because 
the full article was not 
available. (n=1)  
Papers evaluated in detail.       
      (n=10)   
Papers included. (n=10) 
Studies included in the review. 
By independent factor: 
Age and Comorbidity      n=3 
Age        n=2 
Comorbidity      n=2 
Obesity/BMI      n=2 
Sex              n=1 
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List 1: Full List of 34 articles Produced by Original Search 
 
Article Title # 
Grading complication following radical cystectomy and ileal conduit for bladder 
cancer using Clavien grading system. 
Raza SJ, Ather MH, Khan FA, Alam Z. 
J Coll Physicians Surg Pak. 2012 Jul;22(7):448-51. doi: 07.2012/JCPSP.448451. 
PMID: 22747866 
1 
Comorbidity relationship to outcome of radical cystectomy in Chinese: a single 
institution study with the ACE-27 comorbidity index. 
Zhu X, Zhong ZH, Zhang XZ, Zhang L, Zhao XK, Lv C, Xu R, Ren WG, Li SC. 
Asian Pac J Cancer Prev. 2012;13(3):827-31. 
PMID: 22631656 
2 
Does patient age affect survival after radical cystectomy? 
Horovitz D, Turker P, Bostrom PJ, Mirtti T, Nurmi M, Kuk C, Kulkarni G, Fleshner 
NE, Finelli A, Jewett MA, Zlotta AR. 
BJU Int. 2012 May 2. doi: 10.1111/j.1464-410X.2012.11180.x. [Epub ahead of 
print] 
PMID: 22551360 
3 
Robotic-assisted laparoscopic radical cystectomy in the octogenarian. 
Lau CS, Talug J, Williams SB, Josephson DY, Ruel NH, Chan KG, Wilson TG. 
Int J Med Robot. 2012 Jun;8(2):247-52. doi: 10.1002/rcs.460. Epub 2012 Jan 4. 
PMID: 22223357  
4 
Evaluating the utility of a preoperative nomogram for predicting 90-day mortality 
following radical cystectomy for bladder cancer. 
Taylor JM, Feifer A, Savage CJ, Maschino AC, Bernstein M, Herr HW, Donat SM. 
BJU Int. 2012 Mar;109(6):855-9. doi: 10.1111/j.1464-410X.2011.10391.x. Epub 
2011 Jul 1. 
PMID: 21722291 
5 
The role of laparoscopic and robotic cystectomy in the management of muscle-
invasive bladder cancer with special emphasis on cancer control and 
complications. 
Challacombe BJ, Bochner BH, Dasgupta P, Gill I, Guru K, Herr H, Mottrie A, Pruthi 
R, Redorta JP, Wiklund P. 
Eur Urol. 2011 Oct;60(4):767-75. doi: 10.1016/j.eururo.2011.05.012. Epub 2011 
May 17. Review. 
PMID: 21620562 
6 
Re: Khan et al.: analysis of early complications of robotic-assisted 
radical cystectomy using a standardized reporting system (Urology 2011;77:357-
362). 
Donat SM. 
Urology. 2011 Apr;77(4):1016-7; author reply 1017. doi: 
10.1016/j.urology.2010.04.064. No abstract available. 
PMID: 21477742 
7 
[Influence of older age on survival after radical cystectomy due to urothelial 
carcinoma of the bladder: survival analysis of a German multi-centre study after 
curative treatment of urothelial carcinoma of the bladder]. 
May M, Fritsche HM, Gilfrich C, Brookman-May S, Burger M, Otto W, Bolenz C, 
Trojan L, Herrmann E, Michel MS, Wülfing C, Tiemann A, Müller SC, Ellinger J, 
Buchner A, Stief CG, Tilki D, Wieland WF, Höfner T, Hohenfellner M, Haferkamp 
8 
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A, Roigas J, Müller O, Bretschneider-Ehrenberg P, Zacharias M, Gunia S, Bastian 
PJ. 
Urologe A. 2011 Jul;50(7):821-9. doi: 10.1007/s00120-011-2507-9. German. 
PMID: 21340593 
Management of elderly patients with urothelial carcinoma of the bladder: guideline 
concordance and predictors of overall survival. 
Bolenz C, Ho R, Nuss GR, Ortiz N, Raj GV, Sagalowsky AI, Lotan Y. 
BJU Int. 2010 Nov;106(9):1324-9. doi: 10.1111/j.1464-410X.2010.09417.x. 
PMID: 20500510 
9 
Use of radical cystectomy for patients with invasive bladder cancer. 
Gore JL, Litwin MS, Lai J, Yano EM, Madison R, Setodji C, Adams JL, Saigal CS; 
Urologic Diseases in America Project. 
J Natl Cancer Inst. 2010 Jun 2;102(11):802-11. doi: 10.1093/jnci/djq121. Epub 
2010 Apr 16. 
PMID: 20400716 
10 
Treatment and outcome in muscle invasive bladder cancer: a population-based 
survey. 
Leliveld AM, Doornweerd BH, Bastiaannet E, Schaapveld M, de Jong IJ. 
World J Urol. 2010 Aug;28(4):439-44. doi: 10.1007/s00345-010-0546-2. Epub 
2010 Apr 10. 
PMID: 20383640 
11 
Role of patient-physician dialogue in selecting the type of urinary diversion. 
Katkoori D, Manoharan M, Araki M, Soloway MS. 
Urol Int. 2010;84(1):40-4. doi: 10.1159/000273464. Epub 2010 Feb 17. 
PMID: 20173367 
12 
[Long-term follow-up of the defunctionalized bladder after urinary diversion]. 
von Rundstedt FC, Lazica D, Brandt AS, Mathers MJ, Roth S. 
Urologe A. 2010 Jan;49(1):69-74. doi: 10.1007/s00120-009-2144-8. Review. 
German. 
PMID: 19902170 
13 
Aggregate lymph node metastasis diameter and survival after 
radical cystectomy for invasive bladder cancer. 
Stephenson AJ, Gong MC, Campbell SC, Fergany AF, Hansel DE. 
Urology. 2010 Feb;75(2):382-6. doi: 10.1016/j.urology.2009.07.1259. Epub 2009 
Oct 12. 
PMID: 19819539 
14 
Bladder cancer. 
Gallagher DJ, Milowsky MI. 
Curr Treat Options Oncol. 2009 Aug;10(3-4):205-15. doi: 10.1007/s11864-009-
0112-6. Review. 
PMID: 19771524 
15 
Associations between comorbidity, and overall survival and bladder cancer specific 
survival after radical cystectomy: results from the Alberta Urology Institute 
Radical Cystectomy database. 
Fairey AS, Jacobsen NE, Chetner MP, Mador DR, Metcalfe JB, Moore RB, Rourke 
KF, Todd GT, Venner PM, Voaklander DC, Estey EP. 
J Urol. 2009 Jul;182(1):85-92; discussion 93. doi: 10.1016/j.juro.2008.11.111. 
Epub 2009 May 17. 
PMID: 19447413 
16 
Impact of body mass index on clinical and cost outcomes after radical cystectomy. 17 
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Bagrodia A, Grover S, Srivastava A, Gupta A, Bolenz C, Sagalowsky AI, Lotan Y. 
BJU Int. 2009 Aug;104(3):326-30. doi: 10.1111/j.1464-410X.2009.08358.x. Epub 
2009 Feb 11. 
PMID: 19220244 
Feasibility, safety, and efficacy of conservative laparoscopictreatment of borderline 
ovarian tumors. 
Tinelli R, Malzoni M, Cosentino F, Perone C, Tinelli A, Malvasi A, Cicinelli E. 
Fertil Steril. 2009 Aug;92(2):736-41. doi: 10.1016/j.fertnstert.2008.07.1716. Epub 
2008 Sep 14. Review. 
PMID: 18793773  
18 
Impact of body mass index on robot-assisted radical cystectomy. 
Butt ZM, Perlmutter AE, Piacente PM, Wilding G, Tan W, Kim HL, Mohler JL, Guru 
KA. 
JSLS. 2008 Jul-Sep;12(3):241-5. 
PMID: 18765045 
19 
Associations among age, comorbidity and clinical outcomes after 
radical cystectomy: results from the Alberta Urology Institute 
radical cystectomy database. 
Fairey A, Chetner M, Metcalfe J, Moore R, Todd G, Rourke K, Voaklander D, 
Estey E. 
J Urol. 2008 Jul;180(1):128-34; discussion 134. doi: 10.1016/j.juro.2008.03.057. 
Epub 2008 May 15. 
PMID: 18485375 
20 
Age-adjusted Charlson comorbidity score is associated withtreatment decisions 
and clinical outcomes for patients undergoing radical cystectomy for bladder 
cancer. 
Koppie TM, Serio AM, Vickers AJ, Vora K, Dalbagni G, Donat SM, Herr HW, 
Bochner BH. 
Cancer. 2008 Jun;112(11):2384-92. doi: 10.1002/cncr.23462. 
PMID: 18404699 
21 
Gender and age differences in blood utilization and length of stay in 
radical cystectomy: a population-based study. 
Cárdenas-Turanzas M, Cooksley C, Kamat AM, Pettaway CA, Elting LS. 
Int Urol Nephrol. 2008;40(4):893-9. doi: 10.1007/s11255-008-9351-x. Epub 2008 
Mar 4. 
PMID: 18317944 
22 
Results from three municipal hospitals regarding radicalcystectomy on elderly 
patients. 
May M, Fuhrer S, Braun KP, Brookman-Amissah S, Richter W, Hoschke B, Vogler 
H, Siegsmund M. 
Int Braz J Urol. 2007 Nov-Dec;33(6):764-73; discussion 774-6. 
PMID: 18199344 
23 
[Salvage radical prostatectomy]. 
Hautmann RE. 
Urologe A. 2006 Oct;45(10):1260-5. Review. German. 
PMID: 16983529 
24 
Major invasive surgery for urologic cancer in octogenarians with comorbid medical 
conditions. 
Liguori G, Trombetta C, Pomara G, Amodeo A, Bucci S, Garaffa G, Francesca F, 
Belgrano E. 
25 
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Eur Urol. 2007 Jun;51(6):1600-4; discussion 1605. Epub 2006 Aug 11. 
PMID: 16962701 
Management of patients with muscle-invasive and metastatic bladder cancer. 
Henry NL, MacVicar G, Hussain M. 
Oncology (Williston Park). 2005 Sep;19(10):1333-42; discussion 1342, 1347, 1350 
passim. 
PMID: 16285227 
26 
Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a 
population-based study. 
Prout GR Jr, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK. 
Cancer. 2005 Oct 15;104(8):1638-47. 
PMID: 16130136 
27 
Small cell carcinoma of bladder: a single-center prospective study of 25 cases 
treated in analogy to small cell lung cancer. 
Bex A, Nieuwenhuijzen JA, Kerst M, Pos F, van Boven H, Meinhardt W, Horenblas 
S. 
Urology. 2005 Feb;65(2):295-9. 
PMID: 15708041  
28 
[Pelvic recurrence of urothelial tumor, after radical cysto-prostatectomy with 
orthotopic neo-bladder]. 
Pascual Regueiro D, Mallén Mateo E, Trívez Boned MA, García García MA, Gil 
Sanz MJ, Rioja Sanz LA. 
Actas Urol Esp. 2003 Sep;27(8):629-32. Spanish. 
PMID: 14587238 
29 
A study of the morbidity, mortality and long-term survival following 
radical cystectomy and radical radiotherapy in the treatment of invasive bladder 
cancer in Yorkshire. 
Chahal R, Sundaram SK, Iddenden R, Forman DF, Weston PM, Harrison SC. 
Eur Urol. 2003 Mar;43(3):246-57. 
PMID: 12600427 
30 
Prognostic value of angiogenesis in schistosoma-associated squamous cell 
carcinoma of the urinary bladder. 
Elsobky E, El-Baz M, Gomha M, Abol-Enein H, Shaaban AA. 
Urology. 2002 Jul;60(1):69-73. 
PMID: 12100926 
31 
Prognostic-factors-based risk-stratification model for invasive urothelial carcinoma 
of the urinary bladder in Taiwan. 
Yang MH, Yen CC, Chen PM, Wang WS, Chang YH, Huang WJ, Fan FS, Chiou 
TJ, Liu JH, Chen KK. 
Urology. 2002 Feb;59(2):232-8; discussion 238-9. 
PMID: 11834392  
32 
Bladder preservation in adult classic exstrophy: early results of four patients. 
Pathak HR, Mahajan R, Ali NI, Kaul S, Andankar MG. 
Urology. 2001 May;57(5):906-10. 
PMID: 11337291  
33 
Influence of patient age and co-morbidity on outcome of a collaborative care 
pathway after radical prostatectomy and cystoprostatectomy. 
Koch MO, Smith JA Jr. 
J Urol. 1996 May;155(5):1681-4. 
PMID: 8627853 
34 
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List 2: Articles Excluded Based on Title and Abstract 
 
Article Title # Reason for 
exclusion 
Grading complication following radical cystectomy and 
ileal conduit for bladder cancer using Clavien grading 
system. 
Raza SJ, Ather MH, Khan FA, Alam Z. 
J Coll Physicians Surg Pak. 2012 Jul;22(7):448-51. doi: 
07.2012/JCPSP.448451. 
PMID: 22747866 
1 Focuses on 
complications 
associated with ileal 
conduits.  
Evaluating the utility of a preoperative nomogram for 
predicting 90-day mortality following 
radical cystectomy for bladder cancer. 
Taylor JM, Feifer A, Savage CJ, Maschino AC, Bernstein 
M, Herr HW, Donat SM. 
BJU Int. 2012 Mar;109(6):855-9. doi: 10.1111/j.1464-
410X.2011.10391.x. Epub 2011 Jul 1. 
PMID: 21722291 
5 The study focuses on 
the predictive 
strength of the Isbarn 
Nomogram.  
The role of laparoscopic and robotic cystectomy in the 
management of muscle-invasive bladder cancer with 
special emphasis on cancer control and complications. 
Challacombe BJ, Bochner BH, Dasgupta P, Gill I, Guru K, 
Herr H, Mottrie A, Pruthi R, Redorta JP, Wiklund P. 
Eur Urol. 2011 Oct;60(4):767-75. doi: 
10.1016/j.eururo.2011.05.012. Epub 2011 May 17. 
Review. 
PMID: 21620562 
6 Comparison between 
LRC and RRC and 
comorbidities of the 
procedures 
Re: Khan et al.: analysis of early complications of robotic-
assisted radical cystectomy using a standardized 
reporting system (Urology 2011;77:357-362). 
Donat SM. 
Urology. 2011 Apr;77(4):1016-7; author reply 1017. doi: 
10.1016/j.urology.2010.04.064. No abstract available. 
PMID: 21477742 
7 The article is just a 
commentary.   
[Influence of older age on survival after 
radical cystectomy due to urothelial carcinoma of the 
bladder: survival analysis of a German multi-centre study 
after curative treatment of urothelial carcinoma of the 
bladder]. 
May M, Fritsche HM, Gilfrich C, Brookman-May S, Burger 
M, Otto W, Bolenz C, Trojan L, Herrmann E, Michel MS, 
Wülfing C, Tiemann A, Müller SC, Ellinger J, Buchner A, 
Stief CG, Tilki D, Wieland WF, Höfner T, Hohenfellner M, 
Haferkamp A, Roigas J, Müller O, Bretschneider-
Ehrenberg P, Zacharias M, Gunia S, Bastian PJ. 
Urologe A. 2011 Jul;50(7):821-9. doi: 10.1007/s00120-
011-2507-9. German. 
PMID: 21340593 
8 The article is in 
German.  
Management of elderly patients with urothelial carcinoma 9 Objective was to 
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of the bladder: guideline concordance and predictors of 
overall survival. 
Bolenz C, Ho R, Nuss GR, Ortiz N, Raj GV, Sagalowsky 
AI, Lotan Y. 
BJU Int. 2010 Nov;106(9):1324-9. doi: 10.1111/j.1464-
410X.2010.09417.x. 
PMID: 20500510 
study how many 
patients were treated 
according to 
guidelines 
Use of radical cystectomy for patients with invasive 
bladder cancer. 
Gore JL, Litwin MS, Lai J, Yano EM, Madison R, Setodji 
C, Adams JL, Saigal CS; Urologic Diseases in America 
Project. 
J Natl Cancer Inst. 2010 Jun 2;102(11):802-11. doi: 
10.1093/jnci/djq121. Epub 2010 Apr 16. 
PMID: 20400716 
10 Study is a 
comparison of 
survival rates among 
patients who have 
different treatments 
in addition to surgery. 
Treatment and outcome in muscle invasive bladder 
cancer: a population-based survey. 
Leliveld AM, Doornweerd BH, Bastiaannet E, Schaapveld 
M, de Jong IJ. 
World J Urol. 2010 Aug;28(4):439-44. doi: 
10.1007/s00345-010-0546-2. Epub 2010 Apr 10. 
PMID: 20383640 
11 Study looked at what 
characteristics of a 
patient led to 
cystectomy vs. other 
treatment  
Role of patient-physician dialogue in selecting the type of 
urinary diversion. 
Katkoori D, Manoharan M, Araki M, Soloway MS. 
Urol Int. 2010;84(1):40-4. doi: 10.1159/000273464. Epub 
2010 Feb 17. 
PMID: 20173367 
12 Looked at the role of 
patient-physician 
dialogue in making 
treatment decisions. 
[Long-term follow-up of the defunctionalized bladder after 
urinary diversion]. 
von Rundstedt FC, Lazica D, Brandt AS, Mathers MJ, 
Roth S. 
Urologe A. 2010 Jan;49(1):69-74. doi: 10.1007/s00120-
009-2144-8. Review. German. 
PMID: 19902170 
13 Patients did not 
undergo radical 
cystectomy 
Aggregate lymph node metastasis diameter and survival 
after radical cystectomy for invasive bladder cancer. 
Stephenson AJ, Gong MC, Campbell SC, Fergany AF, 
Hansel DE. 
Urology. 2010 Feb;75(2):382-6. doi: 
10.1016/j.urology.2009.07.1259. Epub 2009 Oct 12. 
PMID: 19819539 
14 Study was looking at 
tumor-node-
metastasis 
classification systems 
and associated 
survival.  
Bladder cancer. 
Gallagher DJ, Milowsky MI. 
Curr Treat Options Oncol. 2009 Aug;10(3-4):205-15. doi: 
10.1007/s11864-009-0112-6. Review. 
PMID: 19771524 
15 Review article 
looking at what 
characteristics of an 
older patient best 
indicates treatment 
modality.  
Feasibility, safety, and efficacy of conservative 
laparoscopictreatment of borderline ovarian tumors. 
18 Study looks at 
outcomes of 
61 
 
Tinelli R, Malzoni M, Cosentino F, Perone C, Tinelli A, 
Malvasi A, Cicinelli E. 
Fertil Steril. 2009 Aug;92(2):736-41. doi: 
10.1016/j.fertnstert.2008.07.1716. Epub 2008 Sep 14. 
Review. 
PMID: 18793773  
conservative 
laparoscopic surgery 
on boderline ovarian 
tumors in young 
women.  
Results from three municipal hospitals regarding 
radicalcystectomy on elderly patients. 
May M, Fuhrer S, Braun KP, Brookman-Amissah S, 
Richter W, Hoschke B, Vogler H, Siegsmund M. 
Int Braz J Urol. 2007 Nov-Dec;33(6):764-73; discussion 
774-6. 
PMID: 18199344 
23 The study compares 
perioperative 
complication rates 
among three different 
municipal hospitals.  
[Salvage radical prostatectomy]. 
Hautmann RE. 
Urologe A. 2006 Oct;45(10):1260-5. Review. German. 
PMID: 16983529 
24 Looks at the effects 
of treating with 
external bean 
radiation and 
interstitial radiation 
for prostate cancer.  
Management of patients with muscle-invasive and 
metastatic bladder cancer. 
Henry NL, MacVicar G, Hussain M. 
Oncology (Williston Park). 2005 Sep;19(10):1333-42; 
discussion 1342, 1347, 1350 passim. 
PMID: 16285227 
26 Looks at different 
treatment modalities 
including combined-
modality approaches 
especially among the 
elderly.  
Age and comorbidity impact surgical therapy in older 
bladder carcinoma patients: a population-based study. 
Prout GR Jr, Wesley MN, Yancik R, Ries LA, Havlik RJ, 
Edwards BK. 
Cancer. 2005 Oct 15;104(8):1638-47. 
PMID: 16130136 
27 Looks at how 
comorbidities 
correlate with what 
kind of treatment 
modality is chosen.  
Small cell carcinoma of bladder: a single-center 
prospective study of 25 cases treated in analogy to small 
cell lung cancer. 
Bex A, Nieuwenhuijzen JA, Kerst M, Pos F, van Boven H, 
Meinhardt W, Horenblas S. 
Urology. 2005 Feb;65(2):295-9. 
PMID: 15708041  
28 The study looks at 
the prognosis of 
small cell carcinoma 
of the bladder.  
[Pelvic recurrence of urothelial tumor, after radical cysto-
prostatectomy with orthotopic neo-bladder]. 
Pascual Regueiro D, Mallén Mateo E, Trívez Boned MA, 
García García MA, Gil Sanz MJ, Rioja Sanz LA. 
Actas Urol Esp. 2003 Sep;27(8):629-32. Spanish. 
PMID: 14587238 
29 The article is a single 
case report.  
A study of the morbidity, mortality and long-term survival 
following radical cystectomy and radical radiotherapy in 
the treatment of invasive bladder cancer in Yorkshire. 
Chahal R, Sundaram SK, Iddenden R, Forman DF, 
Weston PM, Harrison SC. 
Eur Urol. 2003 Mar;43(3):246-57. 
30 Study compares the 
outcomes of patients 
who undergo radical 
radiotherapy vs. 
radical cystectomy.  
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PMID: 12600427 
Prognostic value of angiogenesis in schistosoma-
associated squamous cell carcinoma of the urinary 
bladder. 
Elsobky E, El-Baz M, Gomha M, Abol-Enein H, Shaaban 
AA. 
Urology. 2002 Jul;60(1):69-73. 
PMID: 12100926 
31 Looks at prognostic 
value of 
angiogenesis on a 
specific type of 
bladder cancer.  
Prognostic-factors-based risk-stratification model for 
invasive urothelial carcinoma of the urinary bladder in 
Taiwan. 
Yang MH, Yen CC, Chen PM, Wang WS, Chang YH, 
Huang WJ, Fan FS, Chiou TJ, Liu JH, Chen KK. 
Urology. 2002 Feb;59(2):232-8; discussion 238-9. 
PMID: 11834392  
32 The study looks at 
prognostic outcomes 
for different variables, 
not all patients 
underwent radical 
cystectomy.  
Bladder preservation in adult classic exstrophy: early 
results of four patients. 
Pathak HR, Mahajan R, Ali NI, Kaul S, Andankar MG. 
Urology. 2001 May;57(5):906-10. 
PMID: 11337291  
33 The study population 
undergoes a different 
surgical procedure 
than radical 
cystectomy.  
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Appendix 2: STATA Statistical Methods  
 
A. STATA commands used to create dependent variable for morbidity and independent 
numeric variables 
1. Created dependent variable for morbidity = morbdep 
a. Dependent postoperative complication factors that were included in the collated 
morbidity dependent variable: 
i. wound infectious: wndinfd_ind, supinfec_ind, deep SSI, orgspcssi_ind 
and dehis_ind 
ii. pulmonary complications: reintub_ind, oupneumo_ind, pulembol_ind and 
failwean_ind 
iii. renal complications: oprenafl_ind and renainsf_ind 
iv. urinary tract infections: urninfec_ind 
v. neurologic: cnscva_ind, cnscoma_ind, neurodef_ind 
vi. Cardiac: cdarrest_ind, cdmi_ind 
vii. bleeding issues: othdvt_ind 
viii. Sepsis: othsysep_ind, othseshock_ind 
ix. NOT INCLUDED: airway trauma (airtra) and transfusion (othbleed_ind). 
b. Making the morbdep variable STATA commands: 
1. Generate morbdep=. 
2. Replace morbdep=1 if wndinfd_ind==1 | supinfec_ind==1 | nwndinfd==1| 
orgspcssi_ind==1 | dehis_ind==1 | reintub_ind==1 | oupneumo_ind==1 | 
pulembol_ind==1 | failwean_ind==1 | oprenafl_ind==1 | renainsf_ind==1 | 
urninfec_ind==1 | cnscva_ind==1 | cnscoma_ind==1 | neurodef_ind==1 | 
cdarrest_ind==1 | cdmi_ind==1 | othdvt_ind==1 | othsysep_ind==1 | 
othseshock_ind==1 
3. Replace morbdep=0 if wndinfd_ind==0 & supinfec_ind==0 & nwndinfd==0 
& orgspcssi_ind==0 & dehis_ind==0 & reintub_ind==0 & oupneumo_ind==0 
& pulembol_ind==0 & failwean_ind==0 & oprenafl_ind==0 & 
renainsf_ind==0 & urninfec_ind==0 & cnscva_ind==0 & cnscoma_ind==0 & 
neurodef_ind==0 & cdarrest_ind==0 & cdmi_ind==0 & othdvt_ind==0 & 
othsysep_ind==0 & othseshock_ind==0  
 
2. Morbidity with Reoperation =morbdep2 
a. Generate morbdep2=. 
b. replace morbdep2=1 if morbdep==1 or reoperation_ind==1 
c. replace morbdep2=0 if morbdep==0 and reoperation_ind==0 
 
3. Creating dependent variable for mortality = mortdep 
a. Based on year of death reported through 2012.  
1. Generate mortdep=. 
2. replace mortdep=1 if yrdeath==2008 | yrdeath==2009 | yrdeath==2010 | 
yrdeath==2011 | yrdeath==2012 
3. replace mortdep=0 if yrdeath==-99 
 
Morbidity with reoperations counted Morbdep2 0 (None): 736 = 67.28% 
1 (Yes): 358=32.72% 
Mortality based on data of patient deaths up 
until 2012 
Mortdep 0 (Still Alive): 1057=96.53% 
1 (Dead): 38 = 3.47% 
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4. Creating Numeric or Binary Independent Variables 
a. Fnstatus1_ord: 
i. encode fnstatus1, generate (fnstatus1_num) 
ii. generate new fnstatus1_ord=. 
iii. replace fnstatus1_ord=0 if fnstatus1_num==2 
iv. replace fnstatus1_ord=1 if fnstatus1_num==1 
v. replace fnstatus1_ord=2 if fnstatus1_num==3 
vi. codebook fnstatus1_ord 
b. Ventilat_ind: 
i. encode ventilat, generate (ventilat_mid) 
ii. generate ventilat_ind=. 
iii. replace ventilat_ind=0 if ventilat_mid==1 
c. Same for Cpneumon_ind, Hxcopd_ind, Hxchf_ind, Hxangina_ind, Hxmi_ind, 
Prvpci_ind, Prvpcs_ind, Restpain_ind, Hxpvd_ind, Coma_ind, Hxtia_ind, 
Cva_ind, Hemi_ind, Quad_ind, Cvano_ind, Para_ind, Discancr_ind, 
Tumorcns_ind. 
d. Race: use race_collapse and change to numeric 
i. encode race_collapse, generate (race_collapse_mid) 
ii. generate race_collapse_num=. 
iii. replace race_collapse_num=0 if race_collapse_mid==. 
iv. replace race_collapse_num=1 if race_collapse_mid==2 
v. replace race_collapse_num=2 if race_collapse_mid==1 
vi. replace race_collapse_num=3 if race_collapse_mid==4 
vii. replace race_collapse_num=4 if race_collapse_mid==3 
e. Independent variables:  
i. age_num : 90+ is designated by 90  
a. gen age90=1 if age==”90+” 
b. replace age= “90” if age90==1 
ii. sex_ind : male = 0, female = 1  
iii. race_collapse_num: Unknown =0, Hispanic=1, AA=2, White=3, Other=4 
iv. smoke_ind:  No= 0, Yes = 1 
v. etoh_ind: No = 0, Yes = 1 
vi. fnstatus1_ord: Null = 0, partially dependent = 1, independent = 2 
vii. fnstatus2_ord: independent = 0, partially dependent = 1, totally dependent 
= 2 
viii. dyspnea_ord: none = 0, at rest = 1, moderate exertion = 2 
ix. bmi_cat_num: normal = 0, underweight = 1, overweight = 2, obese = 3 
x. Asaclas_ord: 1 = No Disturb, 2 = Mild Disturb, 3 = Severe Disturb, 4 = 
Life Threat 
xi. No= 0, Yes = 1: ventilat_ind cpneumon_ind hxcopd_ind ascites_ind 
hypermed_ind hxchf_ind hxangina_ind hxmi_ind prvpci_ind prvpcs_ind 
restpain_ind hxpvd_ind coma_ind hxtia_ind cva_ind hemi_ind quad_ind 
cvano_ind para_ind dialysis_ind steroid_ind wtloss_ind bleeddis_ind 
transfus_ind chemo_ind radio_ind discancr_ind tumorcns_ind 
xii. Diabetes: None=0, non-insulin use = 1, insulin use = 2 
 
5. Preoperative lab values 
a. Generate prsodm_ord=. 
b. Replace prsodm_ord=1 if prsodm<135, Replace prsodm_ord=0 if prsdom==-99 
c. Replace prsodm_ord=2 if prsodm>=135 & prsodm<=147 
d. Replace prsodm_ord=3 if prsodm>147 
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B. Stepwise Morbidity (morbdep2) Regression 
 
. stepwise, pr(.1): logit morbdep2 age2 sex_ind race_collapse_ind smoke_ind etoh_ind 
fnstatus2_ind dyspnea_ind bmi severeasa lifethreatasa hxcopd_ind hypermed_ind prvpci_ind 
prvpcs_ind diabetes_ind steroid_ind wtloss_ind bleeddis_ind transfus_ind chemo_ind 
discancr_ind prsodm prbun prcreat prbili prsgot pralkph prwbc prhct prplate prptt prpt prinr, or 
                      begin with full model 
p = 0.9980 >= 0.1000  removing etoh_ind 
p = 0.9904 >= 0.1000  removing lifethreatasa 
p = 0.9644 >= 0.1000  removing fnstatus2_ind 
p = 0.9381 >= 0.1000  removing hypermed_ind 
p = 0.9167 >= 0.1000  removing prhct 
p = 0.8937 >= 0.1000  removing hxcopd_ind 
p = 0.8191 >= 0.1000  removing prptt 
p = 0.8552 >= 0.1000  removing prplate 
p = 0.8254 >= 0.1000  removing prwbc 
p = 0.7807 >= 0.1000  removing sex_ind 
p = 0.7000 >= 0.1000  removing pralkph 
p = 0.6383 >= 0.1000  removing smoke_ind 
p = 0.5614 >= 0.1000  removing bleeddis_ind 
p = 0.5226 >= 0.1000  removing discancr_ind 
p = 0.5361 >= 0.1000  removing prsodm 
p = 0.5526 >= 0.1000  removing prsgot 
p = 0.4552 >= 0.1000  removing prbili 
p = 0.3612 >= 0.1000  removing steroid_ind 
p = 0.3441 >= 0.1000  removing severeasa 
p = 0.3212 >= 0.1000  removing prcreat 
p = 0.3013 >= 0.1000  removing prinr 
p = 0.5279 >= 0.1000  removing prpt 
p = 0.2909 >= 0.1000  removing transfus_ind 
p = 0.2145 >= 0.1000  removing age2 
p = 0.2073 >= 0.1000  removing race_collapse_ind 
p = 0.2474 >= 0.1000  removing diabetes_ind 
p = 0.1093 >= 0.1000  removing wtloss_ind 
p = 0.1836 >= 0.1000  removing bmi 
 
Logistic regression                               Number of obs   =        367 
                                                  LR chi2(5)      =      19.40 
                                                  Prob > chi2     =     0.0016 
Log likelihood = -228.25254                       Pseudo R2       =     0.0408 
------------------------------------------------------------------------------ 
    morbdep2 | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   chemo_ind |   .3887948   .1852384    -1.98   0.047     .1528171    .9891658 
  prvpcs_ind |   .3947911   .1836934    -2.00   0.046     .1586023    .9827095 
       prbun |    1.02858   .0138788     2.09   0.037     1.001735    1.056145 
 dyspnea_ind |   1.835804   .6526495     1.71   0.087     .9145642    3.685006 
  prvpci_ind |   2.138279   .8213957     1.98   0.048     1.007128    4.539874 
       _cons |   .3151836   .0892941    -4.08   0.000     .1808886    .5491815 
------------------------------------------------------------------------------ 
lfit, group(10) table: Logistic model for morbdep2, goodness-of-fit test 
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  (Table collapsed on quantiles of estimated probabilities) 
  +--------------------------------------------------------+ 
  | Group |   Prob | Obs_1 | Exp_1 | Obs_0 | Exp_0 | Total | 
  |-------+--------+-------+-------+-------+-------+-------| 
  |     1 | 0.2057 |     8 |   6.0 |    29 |  31.0 |    37 | 
  |     2 | 0.2888 |    11 |  10.0 |    26 |  27.0 |    37 | 
  |     3 | 0.3065 |    12 |  12.1 |    28 |  27.9 |    40 | 
  |     4 | 0.3248 |     7 |  13.4 |    35 |  28.6 |    42 | 
  |     5 | 0.3373 |    12 |  12.3 |    25 |  24.7 |    37 | 
  |-------+--------+-------+-------+-------+-------+-------| 
  |     6 | 0.3564 |    17 |  15.1 |    26 |  27.9 |    43 | 
  |     7 | 0.3760 |    10 |   9.6 |    16 |  16.4 |    26 | 
  |     8 | 0.4233 |    13 |  12.8 |    19 |  19.2 |    32 | 
  |     9 | 0.4971 |    17 |  17.7 |    21 |  20.3 |    38 | 
  |    10 | 0.7971 |    22 |  20.1 |    13 |  14.9 |    35 | 
  +--------------------------------------------------------+ 
       number of observations =       367 
             number of groups =        10 
      Hosmer-Lemeshow chi2(8) =         6.27 
                  Prob > chi2 =         0.6172 
 
. lroc: Logistic model for morbdep2 
number of observations =      367 
area under ROC curve   =   0.6299 
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C: Stepwise Mortality (Mortdep) Regression  
 
. stepwise, pr(.1): logit mortdep age2 sex_ind race_collapse_ind smoke_ind etoh_ind 
fnstatus2_ind dyspnea_ind bmi severeasa lifethreatasa hxcopd_ind hypermed_ind prvpci_ind 
prvpcs_ind diabetes_ind steroid_ind wtloss_ind bleeddis_ind transfus_ind chemo_ind 
discancr_ind prsodm prbun prcreat prbili prsgot pralkph prwbc prhct prplate prptt prpt prinr, or 
note: etoh_ind dropped because of estimability 
note: wtloss_ind dropped because of estimability 
note: bleeddis_ind dropped because of estimability 
note: transfus_ind dropped because of estimability 
note: o.etoh_ind dropped because of estimability 
note: o.wtloss_ind dropped because of estimability 
note: o.bleeddis_ind dropped because of estimability 
note: o.transfus_ind dropped because of estimability 
note: 53 obs. dropped because of estimability 
                      begin with full model 
p = 0.9470 >= 0.1000  removing prpt 
p = 0.9353 >= 0.1000  removing lifethreatasa 
p = 0.8942 >= 0.1000  removing discancr_ind 
p = 0.8843 >= 0.1000  removing prbili 
p = 0.8441 >= 0.1000  removing hypermed_ind 
p = 0.8608 >= 0.1000  removing prplate 
p = 0.8165 >= 0.1000  removing prinr 
p = 0.7583 >= 0.1000  removing dyspnea_ind 
p = 0.7410 >= 0.1000  removing prcreat 
p = 0.6548 >= 0.1000  removing prsgot 
p = 0.5754 >= 0.1000  removing bmi 
p = 0.5817 >= 0.1000  removing hxcopd_ind 
p = 0.5756 >= 0.1000  removing severeasa 
p = 0.5664 >= 0.1000  removing sex_ind 
p = 0.5593 >= 0.1000  removing prbun 
p = 0.5026 >= 0.1000  removing prvpcs_ind 
p = 0.5453 >= 0.1000  removing smoke_ind 
p = 0.2998 >= 0.1000  removing diabetes_ind 
p = 0.3192 >= 0.1000  removing pralkph 
p = 0.3230 >= 0.1000  removing race_collapse_ind 
p = 0.2793 >= 0.1000  removing prvpci_ind 
p = 0.3312 >= 0.1000  removing prsodm 
p = 0.2664 >= 0.1000  removing prhct 
p = 0.2668 >= 0.1000  removing prptt 
p = 0.2244 >= 0.1000  removing fnstatus2_ind 
p = 0.1488 >= 0.1000  removing age2 
 
Logistic regression                               Number of obs   =        314 
                                                  LR chi2(3)      =      13.69 
                                                  Prob > chi2     =     0.0034 
Log likelihood = -50.385109                       Pseudo R2       =     0.1196 
 
------------------------------------------------------------------------------ 
     gmortdep | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
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 steroid_ind |   14.78151   14.66217     2.72   0.007     2.115384    103.2876 
   chemo_ind |   4.240507   3.052183     2.01   0.045     1.034546    17.38144 
       prwbc |   1.106409   .0516774     2.16   0.030     1.009621    1.212476 
       _cons |   .0136697   .0076785    -7.64   0.000      .004546    .0411047 
------------------------------------------------------------------------------ 
 
. lfit, group(10) table ; Logistic model for mortdep, goodness-of-fit test 
 
  (Table collapsed on quantiles of estimated probabilities) 
  +--------------------------------------------------------+ 
  | Group |   Prob | Obs_1 | Exp_1 | Obs_0 | Exp_0 | Total | 
  |-------+--------+-------+-------+-------+-------+-------| 
  |     1 | 0.0218 |     0 |   0.7 |    32 |  31.3 |    32 | 
  |     2 | 0.0236 |     1 |   0.7 |    30 |  30.3 |    31 | 
  |     3 | 0.0249 |     0 |   0.8 |    32 |  31.2 |    32 | 
  |     4 | 0.0267 |     2 |   0.9 |    34 |  35.1 |    36 | 
  |     5 | 0.0281 |     1 |   0.8 |    29 |  29.2 |    30 | 
  |-------+--------+-------+-------+-------+-------+-------| 
  |     6 | 0.0299 |     0 |   0.8 |    28 |  27.2 |    28 | 
  |     7 | 0.0322 |     2 |   1.0 |    29 |  30.0 |    31 | 
  |     8 | 0.0370 |     2 |   1.1 |    30 |  30.9 |    32 | 
  |     9 | 0.0777 |     0 |   1.5 |    31 |  29.5 |    31 | 
  |    10 | 0.5148 |     6 |   5.7 |    25 |  25.3 |    31 | 
  +--------------------------------------------------------+ 
       number of observations =       314 
             number of groups =        10 
      Hosmer-Lemeshow chi2(8) =         7.24 
                  Prob > chi2 =         0.5110 
 
. lroc: Logistic model for mortdep 
 number of observations =      314 
 area under ROC curve   =   0.7251 
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